Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Gliclazide

A second-generation sulfonylurea that prompts the pancreas to release insulin, used for type 2 diabetes. Patented in 1966, it has been in use since 1972. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards, nitrosamines and other impurities.

Did you know?It binds selectively to SUR1 receptors on the beta cells of the pancreas, not to the SUR2A receptors of the heart: it closes potassium channels, and the calcium that then enters the cell triggers insulin release.

GliclazideGo to the active ingredient →
GliclazideActive ingredientGliclazideCat. No. P-G040-001CAS 21187-98-4
Gliclazide-d4Isotopically labelledGliclazide-d4Cat. No. P-G040-009CAS 1185039-30-8

EDQM standards 3

The official European Pharmacopoeia standards for this family.

Reference substanceGliclazide CRSEDQM code G0326000Family Gliclazide

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.